TSE:IMV - IMV Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$5.40 -0.08 (-1.46 %) (As of 03/19/2019 02:56 PM ET)Previous CloseC$5.48Today's RangeC$5.36 - C$5.7752-Week RangeC$5.18 - C$9.49Volume28,459 shsAverage Volume38,079 shsMarket CapitalizationC$276.16 millionP/E Ratio-12.04Dividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email IMV Inc., a clinical-stage immuno-oncology company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is based in Dartmouth, Canada. Receive IMV News and Ratings via Email Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:IMV Previous Symbol CUSIPN/A CIKN/A Webwww.imvaccine.com Phone+1-902-4921819Debt Debt-to-Equity Ratio80.22 Current Ratio4.86 Quick Ratio4.57Price-To-Earnings Trailing P/E Ratio-12.04 Forward P/E Ratio-19.29 P/E GrowthN/A Sales & Book Value Annual SalesC$49,000.00 Price / Sales5,635.84 Cash FlowC$0.45 per share Price / Cash Flow12.00 Book ValueC$0.25 per share Price / Book21.86Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees33 Outstanding Shares51,140,000Market CapC$276.16 million Next Earnings Date3/22/2019 (Confirmed) OptionableNot Optionable IMV (TSE:IMV) Frequently Asked Questions What is IMV's stock symbol? IMV trades on the Toronto Stock Exchange (TSX) under the ticker symbol "IMV." When is IMV's next earnings date? IMV is scheduled to release their next quarterly earnings announcement on Friday, March 22nd 2019. View Earnings Estimates for IMV. What price target have analysts set for IMV? 3 Wall Street analysts have issued 12 month target prices for IMV's shares. Their forecasts range from C$10.40 to C$11.00. On average, they anticipate IMV's share price to reach C$10.70 in the next twelve months. This suggests a possible upside of 98.1% from the stock's current price. View Analyst Price Targets for IMV. What is the consensus analysts' recommendation for IMV? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMV. Has IMV been receiving favorable news coverage? News coverage about IMV stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. IMV earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. Who are some of IMV's key competitors? Some companies that are related to IMV include Mesoblast (MSB), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Theratechnologies (TH), Biotest (BIO), Polynovo (PNV), Oxford BioMedica (OXB), Senesco Technologies (ELOX), Starpharma (SPL), Neptune Wellness Solutions (NEPT), Enochian Biosciences (ENOB), Monash IVF Group (MVF), Kodiak Sciences (KOD), Horizon Discovery Group (HZD) and Emblem (EMC). What other stocks do shareholders of IMV own? Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include International Road Dynamics (IRD), ReNeuron Group (RENE), Medical Facilities (DR), Manulife Financial (MFC), Bombardier, Inc. Class B (BBD.B), Aurora Cannabis (ACB), Extendicare (EXE), Aimia (AIM), eBay (EBAY) and Algonquin Power & Utilities (AQN). Who are IMV's key executives? IMV's management team includes the folowing people: Mr. Frederic Ors, Pres, CEO & Director (Age 45)Mr. Pierre Labbé C.A., C.P.A., CPA, CA, ICD, Chief Financial Officer (Age 54)Dr. Gabriela Nicola Rosu M.D., Chief Medical OfficerMr. Marc Jasmin CPA, CMA, Sr. Director of Investor Relations & CommunicationsMr. Joseph Sullivan, Sr. VP of Bus. Devel. How do I buy shares of IMV? Shares of IMV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is IMV's stock price today? One share of IMV stock can currently be purchased for approximately C$5.40. How big of a company is IMV? IMV has a market capitalization of C$276.16 million and generates C$49,000.00 in revenue each year. IMV employs 33 workers across the globe. What is IMV's official website? The official website for IMV is http://www.imvaccine.com/. How can I contact IMV? IMV's mailing address is 1344 Summer Street, Suite 412, HALIFAX, NS B3H 0A8, Canada. The company can be reached via phone at +1-902-4921819. MarketBeat Community Rating for IMV (TSE IMV)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 58 (Vote Outperform)Underperform Votes: 43 (Vote Underperform)Total Votes: 101MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/19/2019 by MarketBeat.com StaffFeatured Article: What is the Gross Domestic Product (GDP)?